An autocrine cytokine/JAK/STAT-signaling induces kynurenine synthesis in multidrug resistant human cancer cells

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Campia, Ivana ^a   Buondonno, Ilaria ^a   Castella, Barbara ^b   Rolando, Barbara ^b   Kopecka, Joanna ^a   Gazzano, Elena ^a   Ghigo, Dario ^a,b   Riganti, Chiara ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO BRASSININ; CD40 LIGAND; CYTOKINE; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE; JANUS KINASE 1; KYNURENINE; N METHYLTRYPTOPHAN; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN INHIBITOR OF ACTIVATED STAT 3; STAT PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CHAPERONE; JAK1 PROTEIN, HUMAN; PIAS3 PROTEIN, HUMAN; SMALL INTERFERING RNA; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN;

AMINO ACID SYNTHESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CD3+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE; HUMAN; HUMAN CELL; IDO1 GENE; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOCOMPETENCE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BAGG ALBINO MOUSE; CYTOLOGY; DRUG RESISTANCE; GENETICS; HT-29 CELL LINE; IMMUNOLOGY; K-562 CELL LINE; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; T LYMPHOCYTE; TUMOR CELL LINE;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CYTOKINES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HT29 CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; JANUS KINASE 1; K562 CELLS; KYNURENINE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR CHAPERONES; NEOPLASMS; PROTEIN INHIBITORS OF ACTIVATED STAT; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 84945535151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126159     Document Type: Article

References (52)

1. Gottesman MM, Fojo T, Bates SE (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2(1): 48-58. PMID: 11902585
2. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF (2011) Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med 13: E17. doi: 10.1017/S1462399411001888 PMID: 21676290
3. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1): 54-61. PMID: 17187072
4. De Boo S, Kopecka J, Brusa D, Gazzano E, Matera L, Ghigo D, et al. (2009) iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells. Mol Cancer 8: E108.
5. Kopecka J, Campia I, Brusa D, Doublier S, Matera L, Ghigo D, et al. (2011) Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells. J Cell Mol Med 15(7): 1492-1504. doi: 10.1111/j.1582-4934.2010.01137.x PMID: 20716130
6. Riganti C, Castella B, Kopecka J, Campia I, Coscia M, Pescarmona G, et al. (2013) Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells. PLoS One 8(4): E60975. doi: 10.1371/journal.pone.0060975 PMID: 23593363
7. Burkholder B, Huang RY, Burgess R, Luo S, Jones VS, Zhang W, et al. (2014) Tumor-induced perturbations of cytokines and immune cell networks. Biochim Biophys Acta 1845(2): 182-201. doi: 10.1016/j.bbcan.2014.01.004 PMID: 24440852
8. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. (2011) An endogenous tumourpromoting ligand of the human aryl hydrocarbon receptor. Nature 478(7368): 197-203. doi: 10.1038/nature10491 PMID: 21976023
9. Prendergast GC (2011) Cancer: Why tumors eat tryptophan. Nature 478(7368): 192-194. doi: 10. 1038/478192a PMID: 21993754
10. Ozaki Y, Edelstein MP, Duch DS (1988) Induction of indoleamine 2, 3-dioxygenase: A mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 85(4): 1242-1246. PMID: 3124115
11. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2, 3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67(15): 7082-7087. PMID: 17671174
12. Thomas SR, Terentis AC, Cai H, Takikawa O, Levina A, Lay PA, et al. (2007) Post-translational regulation of human indoleamine 2, 3-dioxygenase activity by nitric oxide. J Biol Chem 282(33): 23778-23787. PMID: 17535808
13. Krausse-Opatz B, Wittkop U, Gutzki FM, Schmidt C, Jürgens-Saathoff B, Meier S, et al. (2009) Free iron ions decrease indoleamine 2, 3-dioxygenase expression and reduce IFNgamma-induced inhibition of Chlamydia trachomatis infection. Microb Pathog 46(6): 289-297. doi: 10.1016/j.micpath.2009.03. 001 PMID: 19306922
14. Lu B, Finn OJ (2008) T-cell death and cancer immune tolerance. Cell Death Differ 15(1): 70-79. PMID: 18007660
15. Harden JL, Egilmez NK (2012) Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest 41(6-7): 738-764. doi: 10.3109/08820139.2012.692418 PMID: 22686468
16. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, et al. (2006) Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131-145. PMID: 16972901
17. Uyttenhove C, Pilotte L, Théate I, Stroobant V, Colau D, Parmentier N, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat Med 9(10): 1269-1274. PMID: 14502282
18. Suzuki Y, Suda T, Furuhashi K, Suzuki M, Fujie M, Hahimoto D, et al. (2010) Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer 67(3): 361-365. doi: 10.1016/j.lungcan.2009.05.001 PMID: 19487045
19. Okamoto A, Nikaido T, Ochiai K, Takakura S, Saito M, Aoki Y, et al. (2005) Indoleamine 2, 3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11(16): 6030-6039. PMID: 16115948
20. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, et al. (2006) Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: Effect on tumour-infiltrating T cells. Clin Cancer Res 12(4): 1144-1151. PMID: 16489067
21. Ino K, Tanizaki Y, Kobayashi A, Toujima S, Mabuchi Y, Minami S (2012) Role of the Immune Tolerance-Inducing Molecule Indoleamine 2, 3-Dioxygenase in Gynecologic Cancers. J Cancer Sci Ther 13: E004.
22. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. (2012) IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2(8): 722-735. doi: 10.1158/2159-8290.CD-12-0014 PMID: 22822050
23. Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, et al. (2001) SV40 replication in human mesothelial cells induces HGF/Met receptor activation: A model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 98(21): 12032-12037. PMID: 11572935
24. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. (2007) Inhibition of indoleamine 2, 3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67(2): 792-801. PMID: 17234791
25. Zhang X, He Y, Ding M (2009) Simultaneous determination of tryptophan and kynurenine in plasma samples of children patients with Kawasaki disease by high-performance liquid chromatography with programmed wavelength ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 877 (16-17): 1678-1682.
26. Lee B, French K, Zhuang Y, Smith C (2003) Development of a syngeneic in vivo tumor model and its use in evaluating a novel p-glycoprotein modulator, pgp-4008. Oncol Res 14(1): 49-60. PMID: 14552591
27. Banerjee T, Duhadaway JB, Gaspari P, Sutanto-Ward E, Munn DH, Mellor AL, et al. (2008) A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2, 3-dioxygenase. Oncogene 27(20): 2851-2857. PMID: 18026137
28. Gelsomino G, Corsetto PA, Campia I, Montorfano G, Kopecka J, Castella B, et al. (2013) Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition. Mol Cancer 12: E137.
29. Riganti C, Costamagna C, Doublier S, Miraglia E, Polimeni M, Bosia A, et al. (2008) The NADPH oxidase inhibitor apocynin induces nitric oxide synthesis via oxidative stress. Toxicol Appl Pharmacol 228 (3): 277-285. doi: 10.1016/j.taap.2007.12.013 PMID: 18234259
30. Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, et al. (2009) Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2, 3-dioxygenasemediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 69 (13): 5498-5504. doi: 10.1158/0008-5472.CAN-08-2106 PMID: 19491279
31. Gough DJ, Levy DE, Johnstone RW, Clarke CJ (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19(5-6): 383-394.
32. Orabona C, Grohmann U (2011) Indoleamine 2, 3-dioxygenase and regulatory function: Tryptophan starvation and beyond. Methods Mol Biol 677: 269-280. doi: 10.1007/978-1-60761-869-0-19 PMID: 20941617
33. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, et al. (2009) Cutting edge: Negative regulation of dendritic cells through acetylation of the non histone protein STAT-3. J Immunol 182(10): 5899-5903. doi: 10.4049/jimmunol.0804388 PMID: 19414739
34. Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, Winter M, et al. (2014) Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 5(4): 1038-1051. PMID: 24657910
35. Yadav MC, Burudi EM, Alirezaei M, Flynn CC, Watry DD, Lanigan CM, et al. (2007) IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia 55(13): 1385-1396. PMID: 17661345
36. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, et al. (2012) Interleukin-1β: A new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37(4): 939-949. doi: 10.1038/npp.2011.277 PMID: 22071871
37. Liu WL, Lin YH, Xiao H, Xing S, Chen H, Chi PD, et al. (2014) Epstein-Barr Virus infection induces indoleamine 2, 3-dioxygenase expression in human monocyte-derived macrophages through p38/MAPK and NF-κB pathways: Impairment in T cell functions. J Virol 88(12): 6660-6671. doi: 10.1128/JVI. 03678-13 PMID: 24696473
38. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA (2000) Indoleamine 2, 3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164(7): 3596-3599. PMID: 10725715
39. Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133(5): 775-787. doi: 10.1016/j.cell.2008.05.009 PMID: 18510923
40. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH (2013) Indoleamine 2, 3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. OncoImmunology 2(3): E23428. PMID: 23802083
41. Song L, Rawal B, Nemeth JA, Haura EB (2011) JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 10(3): 481-494. doi: 10.1158/1535-7163.MCT-10-0502 PMID: 21216930
42. Lawrence S, Reid J, Whalen M (2013) Secretion of interferon gamma from human immune cells is altered by exposure to tributyltin and dibutyltin. Environ Toxicol doi: 10.1002/tox.21932
43. Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: From interferons to cytokines. J Biol Chem 282(28): 20059-20063. PMID: 17502367
44. O'Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28(4): 477-487. doi: 10.1016/j.immuni.2008.03.002 PMID: 18400190
45. Russell MA, Cooper AC, Dhayal S, Morgan NG (2013) Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells. Islets 5(2): 95-105. doi: 10.4161/isl. 24249 PMID: 23510983
46. Orabona C, Pallotta MT, Volpi C, Fallarino F, Vacca C, Bianchi R, et al. (2008) SOCS3 drives proteasomal degradation of indoleamine 2, 3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci USA 105(52): 20828-20833. doi: 10.1073/pnas.0810278105 PMID: 19088199
47. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7(1): 41-51. PMID: 17186030
48. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E (2007) Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett 258(2): 181-188. PMID: 17920763
49. Maleki Vareki S, Rytelewski M, Figueredo R, Chen D, Ferguson PJ, Vincent M, et al. (2014) Indoleamine 2, 3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget 5(9): 2778-2791. PMID: 24784564
50. Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, et al. (2008) Overexpression of indoleamine 2, 3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res 14(22): 7251-7259. doi: 10.1158/1078-0432.CCR-08-0991 PMID: 19010841
51. Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R (2011) Indoleamine 2, 3-dioxygenase expression in human cancers: Clinical and immunologic perspectives. Clin Cancer Res 17(22): 6985-6991. doi: 10. 1158/1078-0432.CCR-11-1331 PMID: 22068654
52. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, et al. (2014) Longlasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2, 3 dioxygenase. Clin Cancer Res 20(1): 221-232. doi: 10.1158/1078-0432.CCR-13-1560 PMID: 24218513